MLN-8237

Aurora kinase A inhibitor oncolytic

Gullu Gorgun, T. Hideshima, K. C. Anderson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

(Chemical Equation Presented) Aurora serine/threonine-protein kinases localize in the centrosome and play a crucial role in cell division by regulating chromatid segregation in mitotic cells; moreover, defective chromatid segregation causes genetic instability, leading to tumorigenesis. Aurora kinases were first identified in Xenopus Eg2, yeast Ipl1 and Drosophila aurora. The human genome expresses three members of the mitotic Aurora kinase family: Aurora kinase A, B and C. Although Aurora kinase A and B are highly homologous, their localization and function differ during mitosis. Aurora kinase A and B have been extensively studied due to their overexpression in tumor cells. Since high AURKA gene expression has been correlated with centrosome amplification and Aurora kinase A is required for cytokinesis, defective Aurora kinase A may cause aneuploidy characteristic of tumors. Thus, inhibition of Aurora kinase A may prove to be therapeutically beneficial, and several inhibitors of Aurora kinase A are being tested in early-phase clinical trials. MLN-8237, a selective inhibitor of Aurora kinase A, is currently in phase I/II clinical trials in both adult and childhood solid tumors and hematological malignancies. Here we review the biology of Aurora kinase A and the role of MLN-8237 as a novel therapeutic agent for cancer.

Original languageEnglish (US)
Pages (from-to)903-908
Number of pages6
JournalDrugs of the Future
Volume35
Issue number11
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Aurora Kinase A
Aurora Kinase B
Aurora Kinases
Centrosome
Chromatids
Aurora Kinase C
Neoplasms
MLN 8237
Phase II Clinical Trials
Clinical Trials, Phase I
Cytokinesis
Protein-Serine-Threonine Kinases
Aneuploidy
Human Genome
Hematologic Neoplasms
Xenopus
Mitosis
Cell Division
Drosophila
Carcinogenesis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Gorgun, G., Hideshima, T., & Anderson, K. C. (2010). MLN-8237: Aurora kinase A inhibitor oncolytic. Drugs of the Future, 35(11), 903-908. https://doi.org/10.1358/dof.2010.35.11.1529824

MLN-8237 : Aurora kinase A inhibitor oncolytic. / Gorgun, Gullu; Hideshima, T.; Anderson, K. C.

In: Drugs of the Future, Vol. 35, No. 11, 11.2010, p. 903-908.

Research output: Contribution to journalArticle

Gorgun, G, Hideshima, T & Anderson, KC 2010, 'MLN-8237: Aurora kinase A inhibitor oncolytic', Drugs of the Future, vol. 35, no. 11, pp. 903-908. https://doi.org/10.1358/dof.2010.35.11.1529824
Gorgun, Gullu ; Hideshima, T. ; Anderson, K. C. / MLN-8237 : Aurora kinase A inhibitor oncolytic. In: Drugs of the Future. 2010 ; Vol. 35, No. 11. pp. 903-908.
@article{0601beea576a441689d041df14fd6210,
title = "MLN-8237: Aurora kinase A inhibitor oncolytic",
abstract = "(Chemical Equation Presented) Aurora serine/threonine-protein kinases localize in the centrosome and play a crucial role in cell division by regulating chromatid segregation in mitotic cells; moreover, defective chromatid segregation causes genetic instability, leading to tumorigenesis. Aurora kinases were first identified in Xenopus Eg2, yeast Ipl1 and Drosophila aurora. The human genome expresses three members of the mitotic Aurora kinase family: Aurora kinase A, B and C. Although Aurora kinase A and B are highly homologous, their localization and function differ during mitosis. Aurora kinase A and B have been extensively studied due to their overexpression in tumor cells. Since high AURKA gene expression has been correlated with centrosome amplification and Aurora kinase A is required for cytokinesis, defective Aurora kinase A may cause aneuploidy characteristic of tumors. Thus, inhibition of Aurora kinase A may prove to be therapeutically beneficial, and several inhibitors of Aurora kinase A are being tested in early-phase clinical trials. MLN-8237, a selective inhibitor of Aurora kinase A, is currently in phase I/II clinical trials in both adult and childhood solid tumors and hematological malignancies. Here we review the biology of Aurora kinase A and the role of MLN-8237 as a novel therapeutic agent for cancer.",
author = "Gullu Gorgun and T. Hideshima and Anderson, {K. C.}",
year = "2010",
month = "11",
doi = "10.1358/dof.2010.35.11.1529824",
language = "English (US)",
volume = "35",
pages = "903--908",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - MLN-8237

T2 - Aurora kinase A inhibitor oncolytic

AU - Gorgun, Gullu

AU - Hideshima, T.

AU - Anderson, K. C.

PY - 2010/11

Y1 - 2010/11

N2 - (Chemical Equation Presented) Aurora serine/threonine-protein kinases localize in the centrosome and play a crucial role in cell division by regulating chromatid segregation in mitotic cells; moreover, defective chromatid segregation causes genetic instability, leading to tumorigenesis. Aurora kinases were first identified in Xenopus Eg2, yeast Ipl1 and Drosophila aurora. The human genome expresses three members of the mitotic Aurora kinase family: Aurora kinase A, B and C. Although Aurora kinase A and B are highly homologous, their localization and function differ during mitosis. Aurora kinase A and B have been extensively studied due to their overexpression in tumor cells. Since high AURKA gene expression has been correlated with centrosome amplification and Aurora kinase A is required for cytokinesis, defective Aurora kinase A may cause aneuploidy characteristic of tumors. Thus, inhibition of Aurora kinase A may prove to be therapeutically beneficial, and several inhibitors of Aurora kinase A are being tested in early-phase clinical trials. MLN-8237, a selective inhibitor of Aurora kinase A, is currently in phase I/II clinical trials in both adult and childhood solid tumors and hematological malignancies. Here we review the biology of Aurora kinase A and the role of MLN-8237 as a novel therapeutic agent for cancer.

AB - (Chemical Equation Presented) Aurora serine/threonine-protein kinases localize in the centrosome and play a crucial role in cell division by regulating chromatid segregation in mitotic cells; moreover, defective chromatid segregation causes genetic instability, leading to tumorigenesis. Aurora kinases were first identified in Xenopus Eg2, yeast Ipl1 and Drosophila aurora. The human genome expresses three members of the mitotic Aurora kinase family: Aurora kinase A, B and C. Although Aurora kinase A and B are highly homologous, their localization and function differ during mitosis. Aurora kinase A and B have been extensively studied due to their overexpression in tumor cells. Since high AURKA gene expression has been correlated with centrosome amplification and Aurora kinase A is required for cytokinesis, defective Aurora kinase A may cause aneuploidy characteristic of tumors. Thus, inhibition of Aurora kinase A may prove to be therapeutically beneficial, and several inhibitors of Aurora kinase A are being tested in early-phase clinical trials. MLN-8237, a selective inhibitor of Aurora kinase A, is currently in phase I/II clinical trials in both adult and childhood solid tumors and hematological malignancies. Here we review the biology of Aurora kinase A and the role of MLN-8237 as a novel therapeutic agent for cancer.

UR - http://www.scopus.com/inward/record.url?scp=79956203787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956203787&partnerID=8YFLogxK

U2 - 10.1358/dof.2010.35.11.1529824

DO - 10.1358/dof.2010.35.11.1529824

M3 - Article

VL - 35

SP - 903

EP - 908

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 11

ER -